Introduction
Chemotherapy for the treatment of acquired immunodeficiency syndrome (AIDS) is currently restricted to a single agent, 3'-azido-3'-deoxythymidine (AZl). It has been shown to prolong life as well as to reduce the incidence of opportunistic infections (Fischl et al., 1987) . While effective, a common side-effect is myelosuppression leading to anaemia (Richman et al., 1989) . In addition, it was recently reported that AZT-resistant human immunodeficiency virus (HIV) strains can be isolated from patients following prolonged therapy with this drug (Larder et el., 1989) . Thus, other agents useful in the treatment of AIDS are urgently sought. Dideoxyadenosine (ddA)and its deamination product, dideoxyinosine (ddl), have both shown in vitro activity against HIV . In particular, ddl has shown clinical benefit in a Phase I clinical trial (Yarchoan et al., 1989) .
Like AZT, ddl is a nucleoside analogue and is an inhibitor/substrate of the HIV reverse transcriptase (Rl) after activation by host cell enzymes to the triphosphate ddATP Hao et al., 1988) . However, in contrast to AZT, neither ddA nor ddl is stable at low pH (Anderson et el., 1988) , such as is present in the stomach. This impacts on the oral bioavailability of both compounds, and for ddA this breakdown liberates adenine which is nephrotoxic (Philips et aI., 1952) . Therefore, ddl was developed for clinical investigation, and it is administered together with antacids or buffer to improve the oral bioavailability (Yarchoan et al., 1989) .
An alternative strategy is to introduce acid stability into the molecule itself. This has been achieved by introduction of a 2'-fluoro substitutent into the sugar (Marquez et al., 1987) , which stabilizes the glycosidic bond to hydrolytic cleavage at low pH, while retaining anti-HIV activity of the compound (Herdewijn et al., 1987; Marquez et aI., 1987) .
The metabolism of ddA and ddl in cells has been described elsewhere Cooney et al., 1987; . Deamination of ddA by adenosine deaminase is very rapid, and thus the exposure a. No reaction at 10 mMFddl could be detected even with 100 times more PNP than was used with ddl.
Adenosine deaminase from calf spleen ddA 0.086 FddA 0.374
Cellular pharmacology of FddA/Fddl
In cells, both ddA and ddl are converted to ddATP Cooney et al., 1987; Hao et al., 1988) , an inhibitor of HIV RT (Chen and Oshana, 1987; Hao et al., 1988) . We therefore studied the phosphorylation of FddA and Fddl by CEM cells (Fig. 3 , Table 2 ) using (0.8 fLM) tritium-labelled FddA or Fddl. Ion-exchange HPLC of methanol extracts of cells incubated with the compounds acheivable concentrations (significantly below the K".j the rate of deamination of FddA might be expected to be about 50-fold slower than that of ddA. Fddl and ddl were compared in a human purine nucleoside phosphorylase assay (fable 1). The results show that ddl is a poor substrate for PNP (K m = 3.6mM). By contrast, Fddl is apparently resistant to PNP cleavage since release of hypoxanthine could not be detected even when 10mM Fddl and 100-fold more PNP was used. Previous workers (Stoeckler et al., 1980) have shown ddl to be a poorer substrate (K m~1 2-fold higher and V max 100-fold lower) than inosine.
Since the phosphorylation of ddl has been attributed to the enzyme 5 '-nucleotidase, it was of interest to investigate the activation of Fddl by this enzyme. The enzyme was purified from CEM cells and its ability to phosphorylate Fddl was determined by HPLC analysis of the products from a reaction mixture containing labelled Fddl and unlabelled IMP or ATP or both. The results (Fig. 2) shows that labelled FddlMP is formed when IMP is the phosphate donor. ATP alone is not a phosphate donor in this assay, demonstrating that the phosphorylation is not due to contaminating kinases. Using various concentrations of Fddl in the standard assay (which separates labelled FddlMP from Fddl by TLC), the kinetics of activation were determined (fable 1). The K m of 16mM found for Fddl was fivefold higher than that determined for inosine, but the relative Vmax for both compounds was similar. 
Interaction of FddAlFddl with enzymes
The kinetics of adenosine deaminase degradation of FddA and ddA were determined (fable 1). The binding constant (K".j for FddA is about four-fold poorer than for ddA and the Vmax is also lower (12-fold). Thus, at pharmacologically of cells to either ddA or ddl is equivalent. The fate of ddl is then the result of competition between two enzymes, purine nucleoside phosphorylase (PNP) and 5' -nucleotidase, PNP cleavage takes ddl into a catabolic pathway. By contrast, phosphorylation by 5'-nucleotidase to ddlMP takes it into the anabolic sequence leading to ddATP, the metabolite which inhibits HIV RT (Chen and Oshana, 1987; Hao et al., 1988) . In order to understand some of the activity and biochemical differences between ddAiI and FddAiI which may impact on the clinical utility, we have undertaken studies of their in vitro anti-HIV effect and metabolism at both the level of cells and the four enzymes described above. This report details our findings.
Antiviral activity
The antiviral activities of FddA and Fddl were compared to those of ddA, ddl and AZT (Fig. 1 hand, 0.8 and 5 J-LM Fddl lead to formation of 0.02 and 0.07 f.LM FddATP. In a comparable experiment using the monocytic cell line U937, with 5 f.LM compounds, the HPLC profiles of labelled metabolites were similar to those obtained with CEM cells (Fig. 4b) . The data suggest, however, that these cells may accumulate a two-fold higher concentration of FddATP from FddA and Fddl than is found in CEM cells.
In all the metabolism experiments, peaks of radioactivity at RT = 16, 31 and 50 min were seen. These were produced in consistently higher concentrations from Fddl than from FddA, and were seen to decrease between the 6 and 24 h samples. The retention times were the same as seen for AMP, ADP, and ATP, and it is proposed thatthese are produced by exchange of the labelled hypoxanthine on Fddl (but not adenine on FddA). Since cleavage by PNP was not observed, some other enzyme might be involved in this reaction.
The stability (half-life) of FddATP in U937 cells after removal of extracellular drug was determined. Cells were incubated for 6 h with 5 f.LM FddA and were then washed by centrifugation and resuspended in fresh medium without
.
. Extracted metabolites were analysed by ion-exchange HPLC using System C, and the eluent was fractionated into 1.0-ml samples and counted.
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(a) resolves peaks of material which have elution times typical of mono-, di-and triphosphates. An authentic chemically synthesized sample of FddATP was shown by UV peak to elute at the same retention time as the peak labelled FddATP. FddlTP is assumed to elute about 4 min prior to FddATP since ddlTP elutes about 4 min earlier than ddATP in this system (not shown). Thus it would appear that FddlTP is not formed. This result is consistent with the findings of Cooney et al. (1987) who showed ddlDP and ddlTP were not produced from ddA, and of Masood et al. (1990) who only found phosphorylated form of FddA.
The counts in each peak were used to calculate intracellular concentrations of the metabolites (Table 2) . With both compounds the concentratioon of FddATP did not change significantly from 6 to 24h. However, in CEM cells the concentration of FddATP produced from FddA was about five-fold higher than that produced from Fddl.
With CEM cells exposed for 6 h to a higher concentration (5f.LM) of FddA or Fddl, HPLC profiles of labelled metabolites were similar to those obtained with 0.8 f.LM (Fig. 4a) . However, the concentration of FddATP formed (Table 1) was not significantly different between 0.8 and 5 f.LM FddA (0.14 and 0.18 f.LM, respectively). On the other fit the model of competitive inhibition very well. In this system, ddATP is not a good inhibitor; its affinity for the enzyme is fourfold lower than the natural substrate dATP. FddATP, though, has a much lower affinity (20-fold less potent than ddATP).
Assays using activated salmon sperm DNA as templateprimer provided a system where the K; value for ddATP is lower than the K m for dATP. As can be seen in Table 3 , the K;for ddATP in this system was 0.08 JLM and threefold less than the K m for dATP (0.29JLM). However, the K; for FddATP was 3.0 JLM, which is 40-fold higher than the value for ddATP. compound added. At the intervals shown, cells were processed to determine intracellular concentrations of FddATP (Fig. 5) . The half-life for this metabolite was measured to be 20 h while, in the same cells, the label in the ATP pool decayed with a half-life of 4.5h.
Discussion
The in vitro activities of FddA and Fddl are an order of magnitude less potent than those of ddA and ddl. Nevertheless, ddl is an order of magnitude less potent than AZT in vitro, but in vivo in clinical trials has shown efficacy at similar doses (Yarchoan et al. 1989) . Thus in vitro tests do not give us a complete picture of the antiviral potential in humans.
The manifestation of anti-HIV activity by a nucleoside analogue, is, in general, dependent on the interactions Results reported are the average of at least two separate experiments. 
Effect of FddATP on HIV RT
The anti-HIV activity of ddA and ddl is proposed to result from their conversion to ddATP, which has an inhibitory effect on the viral enzyme RT (Chen and Oshana, 1987; Hao et al., 1988) . Thus it was of interestto compare ddATP and FddATP as inhibitors of this enzyme. The results for the synthetic template-primer, poly(rU):oligo(dA), are shown in Fig. 6 and Table with a number of enzymes. Several (at least three) cellular enzymes are involved in successive phosphorylations to produce the 5 '-triphosphate of the nucleoside analogue. Subsequently, the triphosphate interacts with host or viral DNA polymerases, potentially both as an inhibitor and a substrate. Other enzymes may divert the nucleoside analogue from the anabolic pathway to a catabolic one. In order to characterize the anti-HIV activity of FddA and Fddl we have investigated their cellular metabolism and interactions with some of the enzymes involved in this metabolism.
As shown in Table 1 , deamination of FddA to Fddl by adenosine deaminase is slower than that of ddA to ddl. However, this may have little pharmacological relevance since when FddA is administered, rapid deamination is observed in vivo and the major exposure is to Fddl (Stoltz et al., 1989) . Of greater importance is the resistance of Fddl to PNP, which reduced the loss of free drug to catabolism. ddl is quite readily cleaved by this enzyme, resulting in loss of compound which could potentially be activated to the triphosphate.
Phosphorylation of Fddl to FddlMP by 5 '-nucleotidase occurs readily and, as a substrate, its K m was four-fold higher and Vmax 1.3-fold higher than inosine (relative Vmaxt'K m ratio = 0.3). This is in contrast to what was reported with ddl (Johnson and Fridland, 1989) Where the K m was sixfold lower but V max 50-fold lower than inosine (relative Vmaxt'K m ratio = 0.12), suggesting ddl was a slightly poorer substrate than Fddl.
FddATP and ddATP were both competitive inhibitors with respect to dATP against HIV RT, but FddATP had a higher K j than ddATP by 2Q-40-fold, depending on the template/primer used. This result is consistent with the difference in anti-HIV effects of these compounds in cell cultures Where FddA and Fddl are an order of magnitude less potent than ddA and ddl. Our results for K m and K, values for dATP and ddATP using the synthetic poly(rU):oligo(dA) template primer were 2.4 and 7.9/LM, respectively. These are in close agreement with the values of 2.3 and 5.75/LM reported by Chen and Oshana (1987) using the same template primer and RT purified from HIV lysate. Other reported kinetic data using HIV RT (Hao et al., 1988) are quite different: a Km of 11/LM for dATP and a K; of 0.22/LM for ddATP were obtained. However, the template/primer system, poly (dA-T), was different from the ones used by us. Using this latter system, a K, for FddATP was recently reported as 1 /LM, compared to 0.1/LM for ddATP (Masood et al., 1990) .
The identification of FddATP in cells in this study was made by its co-elution with authentic standards. This is similar to work described recently (Masood et al., 1990 where reaks of putative FddATP and FddAMP eluted with authentic standards. In addition, in that study (Masood et al., 1990 )the liberation of FddA or FddAMP after treatment with alkaline phosphatase or snake venom phospediesterase confirmed the identification.
In all our experiments comparing cellular metabolism of FddA with Fddl, the FddATP concentration was two to fivefold higher with FddA than with Fddl. This may be due to some direct phosphorylation of FddA to FddAMP under the conditions used. At first glance it would appear that this would suggest an advantage for choosing FctdA as the candidate to pursue for clinical development. However, as stated above, FddA is rapidly deaminated in vivo and the majority of the exposure is to Fddl. Thus, an important difference in this study compared to that of Masood et al. (1990) is the finding that Fddl itself can be metabolized to FddATP in cells. Five /LM Fddlleads to production of 0.07 and 0.18/LM FddATP in CEM and U937 cells, respectively, whereas Molt-4 cells produce 0.05/LM ddATP from 5/LM ddl . Five /LM FddA leads to production of 0.18 and 0.28/LM FddATP in CEM and U937 cells, respectively, whereas previous data using Molt-4 cells (Cooney et sl., 1987) show 5/LM ddA leads to production of 0.05/LM ddATP. Importantly, the pattern of phosphorylated derivatives generated intracellularly is consistent with the rate-limiting phosphorylation step being the first one. This type of pattern, which lacks excess metabolite accumulation, is also seen with ddl (Ahluwali et el., 1987) , ddC (Cooney et al., 1986) and D4T (Ho and Hitchcock, 1989) ,and is unlike that seen with AZT where the monophosphate accumulates (Furman et al., 1986) .
It should be noted that all of the FddATP concentrations measured here are at least 1O-foldlower than the lowest K; value we measured against RT. Thus, plasma concentrations of FddA or Fddl in vivo may need to significantly exceed 5/LM to produce an adequate antiviral concentration of the triphosphate. Once formed, however, the triphosphate decays very slowly (tv" = 20 h) in U937 cells. Masood et al. (1990) have also suggested that FddATP decay in Molt-4 cells has a long half-life, with a 50% reduction in intracellular concentration about 8 h after extracellular drug removal. This information is crucial to the proposal for a clinical dosing schedule and might suggest that dosing frequencies of once a day or less may be worthy of investigation. A comparably slow decay of intracellular ddATP has supported the clinical investigation of twice daily dosing for ddl (Yarchoan et al., 1989) . The production of labelled adenine nucleotides (AMP, ADP, ATP) from labelled FddA and Fddl was surprising in view of the chemical and enzymatic stability of the fluoro derivatives. Similar results were described by Masood et al. (1990) but were attributed to contaminating labelled adenine. This seems unlikely in our study because of our purification of labelled FddA and Fddl prior to use and the higher production from Fddl than FddA; the .latter sug- The scheme is based on data shown here and in Masood et al. (1990) and has a proposed direct step from FddlMP to hypoxanthine (Hx).
gests FddlMP might be the precursor for the releaseof the labelled base. One possible mechanism would be by the reversal of the hypoxanthine guanine phosphoribosyl transferase (HGPRT) reaction (Fig.7) ; pyrophosphate with FddlMP could produce hypoxanthine and 2'-arabinofluoro-2' ,3' -deoxy-5' -phosphoribose-1' -diphosphate. Presumably HGPRT-neqative cell mutants could help to identify whether this enzyme plays a role in this phenomenon.
In conclusion, the metabolic pathways for FddA and Fddl are in general similar to those described for ddA and ddl except PNP cleavage was not observed. Thus, if the anti-HIV effect of ddl in vivo is due to its conversion to ddATP in certain cells, FddA and Fddl will also be converted to FddATP in these cells and similar benefits might be anticipated. The resistance to catabolism as well as to acid degradation (Marquez et al., 1987) which leads to higher oral bioavailability (Stoltz et aI., 1989) may, to some extent, offset the inherently lower potency of FddA at the level of triphosphate against HIV reverse transcriptase. Thus further evaluation of the anti-HIV potential of FddA and Fddl is warranted.
Materials and Experimental procedures

Materials
Calf spleen adenosine deaminase, human blood purine nucleoside phosphorylase, xanthine oxidase from buttermilk, adenosine-free base, and xanthine were purchased from the Sigma Chemical Co. (St louis, MO). The HIV RT was a recombinant product purified from cultures of Escherichia coli expressing the cloned HIV-pol gene, and was obtained from Dr K. Moelling, Max Planck Institut (Germany). Polygram CEl 300 PElTlC plates were from Macherey-Nagel, Germany.
2' ,3'-dideoxyadenosine (ddA), 2' ,3'-dideoxyinosine (ddl), 2'-fluoro-ddA (FddA), and 2'-fluoro-ddl (Fddl) were synthesized by Bristol-Myers chemists. ddA-5'-triphosphate (ddATP),2'-deoxycytidine-5'-triphosphate (dCTP), 2'-deoxyguanosine-5'-tri-
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phosphate (dGTP), 2'-deoxythymidine-5'-triphosphate (dTTP) and the template-primer components (ribouridylic acle), were obtained from Pharmacia (Piscataway, NJ). FddA-5'-triphosphate (FddATP) was synthesized by Dr R. Sterzycki, Bristol-Myers Squibb Co.
Activated salmon sperm DNA prepared by a previously described method (Aposhia and Kornberg, 1962) It was supplied as a solution (1 m Ci rnr') in 50% ethanol with a specific activity of 5Ci rnrnol". 3H-FddA was deaminated to 3H-Fddl by adenosine deaminase. The reaction was complete after 15 min at room temperature using 5 J,LI of enzyme (198U mr", 180U mg-1 protein) in a 0.5-ml sample (500J,LCi). The reaction was monitored by HPlC (System A, see below). Both 3H-FddA and 3H-Fddl were purified using this HPlC system immediately prior to use, and were shown to be >99% radiochemical purity.
Antiviral assays
Antiviral activity was measured by inhibition of production of RT. Briefly, CEM cells were infected with HIV-1 (LAV s R U ) and incubated with dilutions of the test compounds for 6 days. Virus present in the supernatant was determined by RT assay using incorporation of [lH]dTTP onto a poly(A):oligo(dn template primer system. Antiviral activity was also determined by measuring the remaining viable cells by formazan production from XTT (Scudiero et al., 1988) .
Enzyme assays
The kinetic constants K m and K, were determined graphically from Lineweaver-Burk and Dixon plots, respectively, and by non-linear least-square iterative curve fitting based on the equation, v = (Vmax X S)/(S+ K m(1 + (I/K;») (Ho and Hitchcock, 1989) .
Adenosine deaminase. Assay of adenosine deaminase activity with adenosine, ddA or FddA was carried out in potassium phosphate buffer, 50mM, pH 7.5, containing various concentrations between 25 and 800 J,LM of the appropriate adenosine nucleoside. The concentrations of nucleosides in the assay mixture were determined by the absorbance at their corresponding xrnax, 259nm (E = 15500M-1 crn"). Ten microlitres of enzyme (1 U mr' in assay buffer containing 1 mg rnr' BSA)were added to the reaction mixture to start the assay. The decrease of absorbance (6.E = 8600 M-1 cm') at 265nm was followed for 5 min at 24°C using a Hewlett Packard 8450A diode array spectrophotometer. The initial reaction rate (averageabsorbance change per second) was obtained and used for K m and V max determination.
Purine nucleoside phosphorylase (PNP).
Cleavage of the glycosidic bond of ddl and Fddl by PNP was determined by a coupled assay with xanthine oxidase. Hypoxanthine released is thus oxidized and the increase in absorbance at 293 nm is followed on a Hewlett Packard spectrophotometer at 24°C. The reaction mixture (1ml) contained 50mM potassium phosphate pH 7.5 and various concentrations between 1 and 10 mM of the appropriate nucleoside. Base line was established by addition of xanthine oxidase and observation of the absorbance at 293 nm until it became constant. Ten microlitres of PNP (1.05U mr") were then added to start the reaction. At the end of the 5 min incubation period, the average absorbance change per second was obtained.
5 '-nucleotidase. The enzyme was purified from CEM cells according to the procedure described by Johnson and Fridland (1989) to a specific activity of 1.1 urnole mg-1 h-1. Assay of the phosphotransferase activity was carried out at 3JOC for 1h. The assay mixture (20 ul) included 50 mMHEPESbuffer pH 7.2, 50 mM MgCI 2, 500mM KCI, 3mM DTI, 5mM IMP, 5mM ATP, 1mM 3H-inosine (1fLCi per assay mix) and 5'-nucleotidase. Reactions were started by addition of 5 fLl of appropriately diluted enzyme solution. Aliquots of 4 fLl were taken at 60 min and spotted on a cellulose PEl TLC plate to stop the reaction. After developing in deionized water the substrates and products were visualized under a short wave UV lamp. The slower moving spots were cut out and eluted with 1 ml of 0.1 M HCI/0.2M KCI solution individually. Four millilitres of Insta Gel-XF scintillant were added to each solution and radioactivity was counted.
For kinetic constant measurements, the concentration of 3H-inosine in assay solutions ranged from 0.5 to 10 mM and for 3H-Fddl from 0.4 to 20 mM. Four-microlitre samples from assay solutions were analysed on TLC plates at 0, 20, 40 and 60 min. The formation of phosphorylated form of 3H-Fddl or 3H-ddl was linear with time. To confirm the actual formation of 3H-inosine monophosphate (IMP) and 3H-FddIMP under these assay conditions, 1 fLl was taken from the residual solution at the end of the kinetic experiment and analysed by HPLC using system C except that the elution gradient buffer was at pH 3.5. The retention times were 4.5, 5.4, 13.6 and 17.6 min for inosine, Fddl, IMP and FddIMP, respectively.
Reverse transcriptase. The incorporation of radiolabelled dATP into two acid-insoluble template-primer systems was measured under conditions of template excess. With poly(rU)oligo(dA) as template-primer system, the 100 fLl reaction mixtures contained 50 mMTris-HCI, pH 7.5, 0.1 mMKCI, 5 mMMgCI2,5 mMDTI, 10 fL9 BSA, 0.25 00 units of (rU)n, 0.25 00 units of (dAh2-18, variable concentrations of 3H-dATP (1.11-5.54fLM) and variable concentrations of ddATP or FddATP (Q-40fLM and 0-300IJ.M, respectively). The reaction was started by adding 10 fLl of a 100-fold diluted enzyme preparation.
To measure incorporation into activated salmon sperm DNA, poly(rU)oligo(dA) was replaced by 20 fL9activated salmon sperm DNA and the reaction mixture was supplemented with 500 fLM of dGTP, dCTP and dTIP. The concentrations of 3H-dATP ranged from 0.17 to 1.1 fLM. The concentration ranges for ddATP and FddATP were 0-0.75fLM and 0-15fLM, respectively. The reaction was started by adding 10 fLl of a 20-fold diluted enzyme preparation.
After incubation at 3JOC for various periods of time, 20 fLl of the reaction mixture spotted onto Whatman cellulose filter papers. The disks were washed five times in ice-cold 5% trichloroacetic a~id/1 % pyrophosphate and once in ethanol. The dried paper dlsks were counted in 4ml of Insta-gel scintillation cocktail.
The enzyme reactions were linear with time in the experiments described.
Cellular pharmacology
FddA and Fddl were added to cells (CEM or U937, 5 x 105/ml) at concentrations of 4 or 50 J.LCi rnr ' (0.8 or 5 J.LM, respectively). After incubation with labelled compound for either 6 or 24h, 10ml of culture were removed from each flask and centrifuged for 15 min at 450 g. The medium was saved while the pellet was resuspended in 10ml PBS. An aliquot was used to determine the cell number by haemocytometer. The centrifugation was repeated and the pellet was then extracted twice with 2 ml 60% methanol for 30 min at -20°C. The supernatants from each methanol extraction were combined, dried (Speed Vac) and resuspended into 300 J.LI H 20, of which 200 J.LI were analysed by HPLC (System C) and 50 J.LI were assayed for total radioactivity using scintillation counting. Aliquots from the medium and PBS washes were analysed for radioactivity by scintillation counting.
HPLC systems
System A: this system was used for purification of labelled FddA and Fddl. It used a Hewlett Packard 1090 HPLC with a Waters RCM 8 x 10 reverse phase C18 cartridge and a gradient of 5-40% acetonitrile in H 20 over 20 min pumped at 1ml rnlrr '. UV detection at 230, 254 and 260nm was used. Fddl (9.7 min) separated from unreacted FddA (12 min) and FddA from adenine and exchanged labelled material.
System B: this system was used to check the purity of 3H-Fddl after purification and to determine if the 3H label exchanged into H 20 during the purification. It was also used to check the medium after each drug was incubated with cells. This system used the Waters HPLC with a solvecon (Whatman no. 4191-015) precolumn, a guard column packed with a pellicular anion exchanger material (Whatman no. 4105-025) and a Whatman Partisil1 0 SAX analytical 25cm column (no. 4226-001). UV absorbance was monitored at 254nm and radioactivity was quantified on-line with a Radiomatic Flo-One-Beta detector. Buffer A was 15 mMKH2P04 pH 5.5 and Buffer B was 700 mMKH 2P04 pH 5.5. A 0-40% Buffer B linear gradient pumped at 1ml min" over 20 min was used to separate FddA (6.6 min) and Fddl (5.5 min).
System C: this system was used to separate the radioactive intracellular metabolites. This was the same as in System 8 except the gradient was longer (0-100% Buffer B over 75 min, 100-0% Buffer B from 75-85 min and then a 15 min re-equilibration time). Radioactivity was quantified by collecting 1-min fractions and counting the entire fraction in a Beckman 6800 scintillation counter.
